Discover 1,436 paid clinical trials in Renton, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,436
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
for
Pancreatic Neuroendocrine Tumor (pNET),
Location: Seattle WA, Portland OR, Vallejo CA, Salt Lake City UT,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT06943755
Phase2, Phase3, Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
for
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT07046078
Phase2, Recruiting
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Seattle WA, Sioux Falls SD, San Antonio TX,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06803680
Phase1, Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
for
Hormone-receptor-positive Breast Cancer,
Location: Seattle WA, Iowa City IA, Houston TX
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06756932
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
for
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL),
Location: Seattle WA, Portland OR, Palo Alto CA, Duarte CA,
Sponsor: Center for International Blood and Marrow Transplant Research
Sex: All
Age: 18 - 66
Code: NCT06859424
Phase2, Recruiting
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Location: Seattle WA, Portland OR, Duarte CA, Dallas TX,
Sponsor: Eureka Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT04864054
Phase1, Phase2, Recruiting
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
for
Myelofibrosis
Location: Seattle WA, Vancouver, Calgary, Salt Lake City UT,
Sponsor: Sumitomo Pharma America, Inc.
Sex: All
Age: 18+
Code: NCT04176198
Phase1, Phase2, Recruiting
Collection of Tissue Samples for Cancer Research
for
Neoplasms, Lymphomas, Multiple Myeloma,
Location: Seattle WA, Iowa City IA, St Louis MO, Indianapolis IN,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0+
Code: NCT00900198
Recruiting
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
for
Advanced Hepatocellular Carcinoma
Location: Seattle WA, Duarte CA, Dallas TX, Chicago IL,
Sponsor: Iterion Therapeutics
Sex: All
Age: 18+
Code: NCT05797805
Phase1, Phase2, Recruiting
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
for
Non-Malignant Neoplasm
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18 - 49
Code: NCT04083183
Phase1, Phase2, Recruiting
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
for
Cytokine Release Syndrome
Location: Seattle WA, Orange CA, Pittsburgh PA, Augusta GA,
Sponsor: CytoAgents, Inc.
Sex: All
Age: 18+
Code: NCT05905328
Phase1, Phase2, Recruiting
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)